Brief: Sorrento’s Partner, Lee’s Pharm, Announces Full Enrollment Of 498 Patients In A Phase III Trial Of Socazolimab
17/05/2022 19:59
May 17 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* SORRENTO’S LICENSE PARTNER, LEE’S PHARM, ANNOUNCES FULL
ENROLLMENT OF 498 PATIENTS IN A PHASE III TRIAL OF SOCAZOLIMAB
(ANTI-PD-L1 ANTIBODY) FOR FIRST-LINE TREATMENT OF
EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC)
Source text for Eikon: urn:newsml:reuters.com:*:nGNX3C1mCX
Further company coverage: SRNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20